CSL Behring [clinicaltrials_resource:09d5c4639ead9f9a37f0e6d6472b943b]
Mikhail Rojavin [clinicaltrials_resource:0448a49ae00df58563548710fc45eea6]Abraham Kroon, MD, PhD [clinicaltrials_resource:1526800ff7e961797416facd992a3b32]Program Director [clinicaltrials_resource:18e1c932722eb88e9a8c493d694cd890]Clinical Epidemiologist [clinicaltrials_resource:1c2baf070e3c0aaf66a144586b7f4efb]Program Coordinator [clinicaltrials_resource:3034dce625e64234567cea55bdc88401]Global Clinical Program Director [clinicaltrials_resource:335bc4ef1dba7e00ce915fd8b258701a]Program Director [clinicaltrials_resource:3c6022ae5b4a7c80195bd82f2c438f54]Alex Veldman, M.D. [clinicaltrials_resource:47f5d204f147954d0d23e4319450d3c5]Alex Veldman [clinicaltrials_resource:48b39a20b28a67562a795e9d8893f8f8]Alex Veldman [clinicaltrials_resource:4b50ed9c92194303923535be78c6311f]Program Director [clinicaltrials_resource:59b6e6b237affef9729939c2350fc418]Senior Director Immonology & Pulmonology, Clinical R&D [clinicaltrials_resource:5dc18258181c94b0706a40e91a20581a]Othmar Zenker, MD [clinicaltrials_resource:670dbf0a540db19b8cd15c32c8a380a6]Program Director Clinical R&D [clinicaltrials_resource:779e139e67bd559086145c908fd7cb41]Iris Jacobs, MD [clinicaltrials_resource:7cb17e649ed1b1caf3c71aacc67387ee]Program Director, Acquired Bleeding [clinicaltrials_resource:86a6c4224ce6948d8c2e36a1729779aa]Denise D'Andrea, M.D. [clinicaltrials_resource:8e1f0b47df624e4ce215fe577e268a2e]Clinical Epidemiologist [clinicaltrials_resource:8eca8c4685f7d6d10931a85346eb70a9]Melvin Berger, MD, PhD [clinicaltrials_resource:97fcc030ee9767bcd9a967c094a50d31]Program Director, Clinical R&D [clinicaltrials_resource:b1b2d7fdb681d6d96d9e5733fd6e5fd2]Global Clinical Program Director [clinicaltrials_resource:c3142f1f61165676ca3c235e670b89a4]Program director Clinical R&D [clinicaltrials_resource:c67b80bd15f6196615dccea15c497275]Alex Veldman [clinicaltrials_resource:e5c96747a68b7d040ffeb96f1b447077]Dr. Denise D'Andrea [clinicaltrials_resource:e5d54c3452067cbc0ff1f8aa7b44c6d6]Program Director, Acquired Bleeding [clinicaltrials_resource:eb97c6b661895b45fe2fdc37ef455e49]Clinical Epidemiologist [clinicaltrials_resource:f685e8a5d63ce86d75fb4f3044804c23]
affiliation [clinicaltrials_vocabulary:affiliation]
Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A [clinicaltrials:NCT00879541]Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease [clinicaltrials:NCT00941616]Rabies Immune Plasma Booster Study [clinicaltrials:NCT01063140]Patient Registry Study of Berinert® in Normal Clinical Practice [clinicaltrials:NCT01108848]Study of Biostate® in Children With Von Willebrand Disease [clinicaltrials:NCT01213446]Study of Biostate® in Children With Hemophilia A [clinicaltrials:NCT01229007]Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) [clinicaltrials:NCT01545076]A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route [clinicaltrials:NCT01576523]An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding [clinicaltrials:NCT02319460]
collaborator [clinicaltrials_vocabulary:collaborator]
Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID) [clinicaltrials:NCT00168012]Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) [clinicaltrials:NCT00168025]clinicaltrials:NCT00168038Prothrombin Complex Concentrate for Anticoagulant Reversal [clinicaltrials:NCT00168077]Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) [clinicaltrials:NCT00168090]clinicaltrials:NCT00261833clinicaltrials:NCT00292981clinicaltrials:NCT00322556clinicaltrials:NCT00419341clinicaltrials:NCT00496262clinicaltrials:NCT00520494clinicaltrials:NCT00542997clinicaltrials:NCT00670007Haemocomplettan® P During Aortic Replacement [clinicaltrials:NCT00701142]A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced) [clinicaltrials:NCT00701545]clinicaltrials:NCT00701662clinicaltrials:NCT00708435clinicaltrials:NCT00719680clinicaltrials:NCT00751621clinicaltrials:NCT00803101Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A [clinicaltrials:NCT00879541]clinicaltrials:NCT00883090clinicaltrials:NCT00885742Fibrinogen Concentrate (Human) − Efficacy and Safety Study [clinicaltrials:NCT00916656]Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease [clinicaltrials:NCT00941616]clinicaltrials:NCT00945906Health Related Quality of Life of Youth and Young Adults With Hemophilia A [clinicaltrials:NCT01034904]Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study) [clinicaltrials:NCT01053169]Quality of Life Study of Helixate NexGen [clinicaltrials:NCT01053715]Rabies Immune Plasma Booster Study [clinicaltrials:NCT01063140]Patient Registry Study of Berinert® in Normal Clinical Practice [clinicaltrials:NCT01108848]Retrospective Chart Review of Subcutaneous IgG Use in Infants [clinicaltrials:NCT01166074]clinicaltrials:NCT01184846clinicaltrials:NCT01199705Study of Biostate® in Children With Von Willebrand Disease [clinicaltrials:NCT01213446]Extension Study of Biostate in Subjects With Von Willebrand Disease [clinicaltrials:NCT01224808]Study of Biostate® in Children With Hemophilia A [clinicaltrials:NCT01229007]Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B [clinicaltrials:NCT01233440]Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis [clinicaltrials:NCT01347190]A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B [clinicaltrials:NCT01361126]
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
organization [clinicaltrials_vocabulary:organization]
Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID) [clinicaltrials:NCT00168012]Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) [clinicaltrials:NCT00168025]clinicaltrials:NCT00168038Prothrombin Complex Concentrate for Anticoagulant Reversal [clinicaltrials:NCT00168077]Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) [clinicaltrials:NCT00168090]clinicaltrials:NCT00261833clinicaltrials:NCT00292981clinicaltrials:NCT00322556clinicaltrials:NCT00419341clinicaltrials:NCT00496262clinicaltrials:NCT00520494clinicaltrials:NCT00542997clinicaltrials:NCT00670007Haemocomplettan® P During Aortic Replacement [clinicaltrials:NCT00701142]A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced) [clinicaltrials:NCT00701545]clinicaltrials:NCT00701662clinicaltrials:NCT00708435clinicaltrials:NCT00719680clinicaltrials:NCT00751621clinicaltrials:NCT00803101Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A [clinicaltrials:NCT00879541]clinicaltrials:NCT00883090clinicaltrials:NCT00885742Fibrinogen Concentrate (Human) − Efficacy and Safety Study [clinicaltrials:NCT00916656]Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease [clinicaltrials:NCT00941616]clinicaltrials:NCT00945906Health Related Quality of Life of Youth and Young Adults With Hemophilia A [clinicaltrials:NCT01034904]Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study) [clinicaltrials:NCT01053169]Quality of Life Study of Helixate NexGen [clinicaltrials:NCT01053715]Rabies Immune Plasma Booster Study [clinicaltrials:NCT01063140]Patient Registry Study of Berinert® in Normal Clinical Practice [clinicaltrials:NCT01108848]Retrospective Chart Review of Subcutaneous IgG Use in Infants [clinicaltrials:NCT01166074]clinicaltrials:NCT01184846clinicaltrials:NCT01199705Study of Biostate® in Children With Von Willebrand Disease [clinicaltrials:NCT01213446]Extension Study of Biostate in Subjects With Von Willebrand Disease [clinicaltrials:NCT01224808]Study of Biostate® in Children With Hemophilia A [clinicaltrials:NCT01229007]Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B [clinicaltrials:NCT01233440]Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis [clinicaltrials:NCT01347190]A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B [clinicaltrials:NCT01361126]
source [clinicaltrials_vocabulary:source]
CSL Behring [clinicaltrials_resource:09d5c4639ead9f9a37f0e6d6472b943b]
Bio2RDF identifier
09d5c4639ead9f9a37f0e6d6472b943b
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:09d5c4639ead9f9a37f0e6d6472b943b
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:09d5c4639ead9f9a37f0e6d6472b943b
title
CSL Behring
@en
type
label
CSL Behring [clinicaltrials_resource:09d5c4639ead9f9a37f0e6d6472b943b]
@en